Greenlight Capital’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Greenlight Capital’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$101K	Hold	136,350	–	–	﹤0.01%	37
2023 Q3	$119K	Hold	136,350	–	–	0.01%	35
2023 Q2	$255K	Sell	136,350 -1	-0%	-$3	0.01%	36
2023 Q1	$505K	Hold	136,351	–	–	0.03%	35
2022 Q4	$519K	Hold	136,351	–	–	0.04%	33
2022 Q3	$1.08M	Hold	136,351	–	–	0.08%	33
2022 Q2	$2.86M	Hold	136,351	–	–	0.22%	32
2022 Q1	$5.13M	Hold	136,351	–	–	0.33%	30
2021 Q4	$7.66M	Hold	136,351	–	–	0.44%	29
2021 Q3	$9.84M	Hold	136,351	–	–	0.66%	23
2021 Q2	$13.1M	Buy	136,351 +35,000	+35%	+$3.87M	0.82%	24
2021 Q1	$15M	Hold	101,351	–	–	1.04%	22
2020 Q4	$14.2M	Hold	101,351	–	–	0.85%	23
2020 Q3	$15.4M	Buy	101,351 +6,190	+7%	+$1.01M	1.26%	19
2020 Q2	$16.7M	Buy	95,161 +18,238	+24%	+$3.05M	1.81%	12
2020 Q1	$11M	Hold	76,923	–	–	1.56%	14
2019 Q4	$11.1M	Hold	76,923	–	–	0.82%	16
2019 Q3	$7.68M	Buy	+76,923	New	+$7.59M	0.55%	19

Other funds holding NBSE

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Greenlight Capital's NBSE Position: Q4 2023 in Review

Greenlight Capital held its NeuBase Therapeutics, Inc. Common Stock (NBSE) position steady in Q4 2023 at 136,350 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #37.

Greenlight Capital first reported a position in NBSE in Q3 2019 and has held it in 18 quarters since. The position peaked at $16.7M in Q2 2020. 22 funds tracked by Wall St. Rank hold NBSE as of Q4 2023.

Greenlight Capital held 136,350 shares of NeuBase Therapeutics, Inc. Common Stock worth $101K as of Q4 2023.
Greenlight Capital left its NeuBase Therapeutics, Inc. Common Stock share count unchanged in Q4 2023.
NeuBase Therapeutics, Inc. Common Stock made up ﹤0.01% of Greenlight Capital's portfolio in Q4 2023, its #37 holding.
Greenlight Capital first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2019 and has held it in 18 quarters since.
Greenlight Capital's NeuBase Therapeutics, Inc. Common Stock position peaked at $16.7M in Q2 2020.
22 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Greenlight Capital's 13F filing for Q4 2023, filed 14 Feb 2024.